The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
about
The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysisTowards decision-making using individualized risk estimates for personalized medicine: A systematic review of genomic classifiers of solid tumors.Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea.Impact of multigene assays in early stage breast cancer.The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signaturesClinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidenceComparative Effectiveness of Biomarkers to Target Cancer Treatment: Modeling Implications for Survival and CostsImpact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey.Breast cancer genomics: challenges in interpretation and application.The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield.Meta-analysis of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ.Gene-Expression-Based Predictors for Breast Cancer.21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.Integrated precision medicine: the role of electronic health records in delivering personalized treatment.GENE EXPRESSION PROFILING AND EXPANDED IMMUNOHISTOCHEMISTRY TESTS TO GUIDE SELECTION OF CHEMOTHERAPY REGIMENS IN BREAST CANCER MANAGEMENT: A SYSTEMATIC REVIEW.An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.Estimating the OncotypeDX score: validation of an inexpensive estimation tool.Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.Expert opinion: future frontiers and challenges in cancer medicine.Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland.Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.Correlations Between Oncotype DX Recurrence Score and Classic Risk Factors in Early Breast Cancer: Results of A Prospective Multicenter Study in TurkeyUse of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors.Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.Clinical Application of Detecting 21-Gene Recurrence Score in Predicating Prognosis and Therapy Response of Patients with Breast Cancer from Two Medical Centers.Influence of provider factors and race on uptake of breast cancer gene expression profiling.Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.The 21-Gene Recurrence Score in Male Breast Cancer.Impact of Oncotype DX testing on adjuvant treatment decisions in patients with early breast cancer: a single-center study in the United Arab Emirates.
P2860
Q26861418-14A2F9A4-E591-4AA5-AAB8-3CFD5A7BADB4Q30252422-A9A036F8-38C1-42E3-8365-5C5D2F91A7A9Q33915023-D79B9EF8-571A-4C31-AD5B-344FEA5E9F7BQ35430076-2CB0F936-9B82-4664-B31D-9ED2AA3EAB14Q35599759-41E31ED4-12EF-4E31-8B1E-76AC2FA52AB1Q36089048-8F4ECBBD-A019-475A-A8CE-4EFA5A9ACBEEQ36424052-8A45B2AE-6000-43C3-AAD9-21D10E3A10D1Q36462893-BDEAE845-CAB9-422D-9DF0-D4E1939B8A2FQ36614650-34F07E79-82D4-4321-A38E-CE31DADC5502Q36791866-731161DA-D04C-4A90-80EB-CCFEF7681EABQ36804553-A3F58580-CF87-4385-89BE-0D66C675A77EQ36997719-4EDCE37B-CDCD-44D1-88AD-E5919F074BA4Q38024305-503946E6-701C-40A6-8FE2-D2DC3A92EB9CQ38091371-253CB001-E959-4853-B5A9-6F4BACD2965BQ38446055-059967A2-76CA-46DB-9145-75F9D9067E75Q38555220-A6EA47C0-A583-403B-B225-A73EABDEE907Q38681547-AC5B2626-5083-4AC4-B5EB-DF1E8FE9C48DQ38731624-8B02BFB8-18FE-41EA-9DE8-B4673AD315C4Q38747402-0F967C8B-D184-4C61-AF0E-82E1B90B9706Q38756680-FEF8F05D-D6F7-4642-8B9D-656299A8B353Q38795484-BC3120C6-171F-4FA0-8F40-A8D0303598C5Q39015485-5D555F48-D492-4AE9-B125-D277703B3B22Q39106167-E3306973-C21E-44B2-9BB4-BCDBBA1079D8Q39121120-6C511CC8-EF75-4EF7-BB3D-99676D68B239Q39489143-8E9AA58C-27ED-4C12-9ABC-951C10EA38E7Q39612503-A6151F2E-719A-4546-80B5-5403976AFF2AQ41367403-D3AE1BB6-627F-42DB-BA51-42FF382A61DCQ41476022-4E7BA059-20E5-48BF-A6F3-F1F46E361F27Q41823897-A808492A-2460-4075-A425-9AFE522972F0Q42670058-24DB272D-031B-424C-958F-B1FB567D8AF8Q45057063-D32D85C9-F5AF-4E3F-B653-2F165F80B2E0Q46046685-45BA3BA8-6B16-4896-B28B-93C697295F0BQ47204606-826116A3-658A-407E-A041-3A95AF5163A9Q48110842-F68D5942-BB54-45A5-BC79-0F0074F7643BQ48234815-1F86DCFF-9DDD-4DE5-A986-131B07B02396Q49843589-60FCA203-E860-4936-BB80-2E94982ECCDDQ50869231-5708D6B6-D34A-4FA6-83AD-5F603C6CC0BEQ50921836-C691C280-65A0-47E3-9066-47928D018484Q52665411-D6F63882-564F-4035-95B0-BB33B275F4B1Q54191141-455ACC4D-B825-4EBD-95E6-BB91CCDD1795
P2860
The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The effect of Oncotype DX recu ...... by breast cancer specialists.
@ast
The effect of Oncotype DX recu ...... by breast cancer specialists.
@en
type
label
The effect of Oncotype DX recu ...... by breast cancer specialists.
@ast
The effect of Oncotype DX recu ...... by breast cancer specialists.
@en
prefLabel
The effect of Oncotype DX recu ...... by breast cancer specialists.
@ast
The effect of Oncotype DX recu ...... by breast cancer specialists.
@en
P2093
P2860
P1433
P1476
The effect of Oncotype DX recu ...... by breast cancer specialists.
@en
P2093
Carol Reynolds
Christine Laronga
Hatem Soliman
Jennifer E Joh
John V Kiluk
Judy C Boughey
Loretta Loftus
Lucio Gordan
M Catherine Lee
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0045
P577
2011-10-20T00:00:00Z